Intellia Therapeutics (NTLA) Q3 2024 earnings summary

Executive summary

• Achieved significant clinical progress in CRISPR-based gene editing, with positive Phase 2 results for NTLA-2002 in hereditary angioedema (HAE) and rapid advancement of late-stage trials for ATTR amyloidosis and alpha-1 antitrypsin deficiency (AATD); pivotal Phase 3 trials for NTLA-2001 and NTLA-2002 are enrolling ahead of projections, and NTLA-3001 is entering first-in-human studies.

• FDA cleared IND for MAGNITUDE-2 Phase 3 trial in hereditary ATTR amyloidosis with polyneuropathy; study initiation imminent.

• Collaboration revenue is the sole source of revenue to date, with major partners including Regeneron, Sparing Vision, AvenCell, Kyverna, and ReCode.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $944.7 million as of September 30, 2024, down from $1 billion at year-end 2023, primarily due to $335 million in operational spending.

• Collaboration revenue was $9.1 million in Q3 2024, down from $12 million in Q3 2023, mainly due to reduced AvenCell agreement revenue.

• R&D expenses rose to $123.4 million (from $113.7 million), and G&A expenses increased to $30.5 million (from $29.4 million) year-over-year, both driven by program advancement and stock-based compensation.

• Net loss for Q3 2024 was $135.7 million ($1.34/share), compared to $122.2 million ($1.38/share) in Q3 2023.

• Cash runway expected to fund operations into late 2026.

Outlook and guidance

• BLA submission for NTLA-2002 in HAE planned for 2026, with Phase 3 HALO/HAELO study expected to enroll rapidly.

• Three Phase 3 studies anticipated to be underway by year-end, positioning the company as a leader in in vivo CRISPR-based medicines.

• First patient dosing for NTLA-3001 in AATD expected by year-end, with potential data readout in 2025.